Navigation Links
Intercell Announces Q4 and Preliminary Full Year 2009 Financial Results
Date:3/2/2010

uct on the market.

The Company's technology platforms include an antigen-discovery system, adjuvants and a novel patch-based delivery system (Vaccine Patch, Vaccine Enhancement Patch). Based on these technologies, Intercell has strategic partnerships with a number of global pharmaceutical companies, including GSK, Novartis, Merck & Co., Inc., sanofi-aventis, and Pfizer (formerly Wyeth).

The Company's pipeline of investigational products includes a Travelers' Diarrhea Vaccine Patch (Phase III), a Pseudomonas vaccine candidate (Phase II), a vaccine to prevent Pandemic Influenza combining our Vaccine Enhancement Patch with an injected vaccine (Phase II), a vaccine program for S. aureus, which is being developed with Merck & Co., Inc. (Phase II/III), as well as a vaccine candidate for Pneumococcus (Phase I). In addition, further products focused on infectious diseases are in pre-clinical development.

Intercell is listed on the Vienna stock exchange under the symbol "ICLL" (U.S. level one ADR symbol "INRLY").

For more information, please visit

SOURCE Intercell AG
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Intercell Announces European Approval of New Vaccine, IXIARO(R), to Prevent Japanese Encephalitis
2. Intercell to Host Conference Call and Webcast Today on FDA Approval of IXIARO(R) Japanese Encephalitis Vaccine
3. Intercell Announces FDA Approval of IXIARO(R), a Novel Vaccine to Prevent Japanese Encephalitis
4. Australian Authorities (TGA) First to Grant Final Product Approval for Intercells Vaccine to Prevent Japanese Encephalitis
5. Iomai Stockholders Approve Merger With Intercell Subsidiary
6. Iomai, Intercell Chief Scientific Officers to Speak on Future of Vaccines at BIO International Convention Today
7. RESolutions Rapid Enrollment Solutions, LLC Announces Launch of Novel Patient Recruitment Web Site - Clinical Trial Spotlight™
8. Neogen Corporation Announces 3rd Quarter Results Conference Call
9. Raising Awareness of Rare Diseases, Anson Group Announces Sponsorship of Rare Disease Day
10. Shire Announces FDA Approval of VPRIV(TM) (velaglucerase alfa for injection) for the Treatment of Type 1 Gaucher Disease
11. Texas-Based Consortium Announces Project GreenVax: A Groundbreaking Vaccine Manufacturing Research Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... January 15, 2014 This webinar ... on nonclinical and clinical safety assessment in biosimilars. ... guide a path for biosimilar drug development, however ... of biosimilarity with regards to quality, safety and ... of biosimilar drug development and registration, development strategies ...
(Date:1/15/2014)... NC (PRWEB) January 15, 2014 ... an enhancement to its Online Web Portal for Life ... now have the ability to specify the subject matter ... nearly 50 life science sub-domains. This will help reduce ... and scientific fields, and decrease the likelihood of error. ...
(Date:1/14/2014)... Doylestown, PA (PRWEB) January 14, 2014 ... – 11 p.m. , Location: Warrington Country Club, 1360 ... Hepatitis B Foundation, the only national nonprofit organization solely ... improving the quality of life for those affected worldwide, ... 11 at Warrington Country Club in Warrington, Pa. ...
(Date:1/14/2014)... York, NY (PRWEB) January 14, 2014 ... initiated coverage of Alliqua, Inc. (OTCQB: ALQA). Alliqua ... and marketing proprietary products to serve the wound ... , In late 2012, Alliqua was restructured ... launched the company’s new strategy to become a ...
Breaking Biology Technology:Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2DTS Improves Efficiency for Life Science Document Translations 2Hepatitis B Foundation to Host Annual Crystal Ball Gala 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3
... - EastMed Inc., the medical manufacturing company that caters ... clearance to market its flagship product, uresta(TM) Continence Care, ... to get the official word from the FDA," said ... (TM) Continence Care offers an innovative and cost-effective option ...
... Nov. 25 /PRNewswire/ - Aegera Therapeutics Inc. today announced ... the XIAP antisense oligonucleotide, AEG35156, will be highlighted in ... the American Society of Hematology (ASH) in San Francisco, ... presentation is entitled "Phase I/II Trial of the XIAP ...
... a business unit of DSM Pharmaceutical Products, and Dutch,biotechnology company ... today announced that Hungary-based Gedeon Richter Plc. signed a,commercial license ... the PER.C6(R) platform. , ... About PER.C6(R) technology , ...
Cached Biology Technology:Aegera Therapeutics' phase 1/2 clinical trial results selected for oral presentation at 2008 ASH Annual Meeting 2Aegera Therapeutics' phase 1/2 clinical trial results selected for oral presentation at 2008 ASH Annual Meeting 3DSM Biologics and Crucell Announce Commercial PER.C6(R) Licensing Agreement with Gedeon Richter 2DSM Biologics and Crucell Announce Commercial PER.C6(R) Licensing Agreement with Gedeon Richter 3DSM Biologics and Crucell Announce Commercial PER.C6(R) Licensing Agreement with Gedeon Richter 4
(Date:4/14/2014)... David Kisailus, the Winston Chung Endowed Chair ... Riverside,s Bourns College of Engineering, has been named ... scientists selected by the advisory board of the ... Sciences and organizers of the Kavli/National Academy of ... Foundation, which is based in Oxnard, supports scientific ...
(Date:4/14/2014)... you feel when an elevator zips you up multiple floors ... elevator carried you all the way up to the top ... , That,s similar to what many fish experience when they ... the change in pressure is simply too big, too fast, ... article in the March issue of the journal Fisheries ...
(Date:4/14/2014)... Chicago,s Field Museum and international collaborators have reconstructed the ... the New World tropics, the region of the Earth ... nuclear DNA sequences uncovered three species new to science, ... Since 1960, when modern studies on this group began, ... 22. The newest additions were described in a ...
Breaking Biology News(10 mins):Professor receives young scientist honor 2Making dams safer for fish around the world 2Making dams safer for fish around the world 3Making dams safer for fish around the world 4Making dams safer for fish around the world 5Three new species of yellow-shouldered bats discovered in museum collections 2Three new species of yellow-shouldered bats discovered in museum collections 3
... to new research funded by the Economic and Social ... Open University, led by Professor Andy Lane, has taken ... not those mainly involved in organic growing - ... and the food industry regard GM, but this is ...
... is the ultimate destination for anyone interested in natural history ... broadly about our responsibilities to all life on Earth. Thats ... and the Environment at The University of Nottingham, who has ... Observer for the International Association of Antarctica Tour Operators (IAATO). ...
... Now think of bacteria eating rock below the ocean ... 15,000 feet underwater" With a $3.9 million grant ... Katrina Edwards will lead a first-of-its-kind drilling expedition to ... which live on chemical reactions with rock and water, ...
Cached Biology News:What farmers think about GM crops 2Observing sustainable tourism in Antarctica 2Observing sustainable tourism in Antarctica 3USC awarded $3.9M for lab under the sea 2
In plasmid or lambda vector. Please inquire for more details!...
NANS Immunogen: NANS (NP_061819, 260 a.a. ~ 360 a.a) partial recombinant protein with GST tag. Storage: -20 C, Avoid Freeze/Thaw Cycles *Available for distribution in the US only...
Anti-Mouse D011.10 TCR, Biotin (Clone KJ1-26) (mouse IgG2a)...
... SARA ( Abpromise for all tested ... peptide: PVPKEMEQPV QTEEEDVELP conjugated to KLH, corresponding ... (Drosophila melanogaster) SARA. Conserved sequence unique ... ID: 9372 Swiss ...
Biology Products: